BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 9750520)

  • 1. [Steroidal and nonsteroidal antiandrogens: chemical structures, mechanisms of action and clinical applications].
    Akakura K; Furuya Y; Ito H
    Nihon Rinsho; 1998 Aug; 56(8):2124-8. PubMed ID: 9750520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Application of antiandrogens on prostatic diseases].
    Takahashi S; Hasegawa F; Isurugi K
    Nihon Rinsho; 1994 Mar; 52(3):809-14. PubMed ID: 7513031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prostatic hypertrophy and prostate cancer].
    Meguro N
    Nihon Rinsho; 2008 Jan; 66(1):182-5. PubMed ID: 18186262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer.
    Blackledge G; Kolvenbag G; Nash A
    Anticancer Drugs; 1996 Jan; 7(1):27-34. PubMed ID: 8742095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy.
    Migliari R; Muscas G; Murru M; Verdacchi T; De Benedetto G; De Angelis M
    Arch Ital Urol Androl; 1999 Dec; 71(5):293-302. PubMed ID: 10673793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors.
    Urushibara M; Ishioka J; Hyochi N; Kihara K; Hara S; Singh P; Isaacs JT; Kageyama Y
    Prostate; 2007 Jun; 67(8):799-807. PubMed ID: 17373727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
    Sakai H; Igawa T; Tsurusaki T; Yura M; Kusaba Y; Hayashi M; Iwasaki S; Hakariya H; Hara T; Kanetake H
    Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action.
    Furr BJ; Tucker H
    Urology; 1996 Jan; 47(1A Suppl):13-25; discussion 29-32. PubMed ID: 8560673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Total androgen blockade].
    Namiki M; Mizokami A
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():193-8. PubMed ID: 12599570
    [No Abstract]   [Full Text] [Related]  

  • 11. Pure antiandrogens as monotherapy in prospective studies of prostatic carcinoma.
    Schröder FH
    Prog Clin Biol Res; 1990; 359():93-103; discussion 105-7. PubMed ID: 2149460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer.
    Mahler C; Verhelst J; Denis L
    Clin Pharmacokinet; 1998 May; 34(5):405-17. PubMed ID: 9592622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen receptor is targeted to distinct subcellular compartments in response to different therapeutic antiandrogens.
    Whitaker HC; Hanrahan S; Totty N; Gamble SC; Waxman J; Cato AC; Hurst HC; Bevan CL
    Clin Cancer Res; 2004 Nov; 10(21):7392-401. PubMed ID: 15534116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormonal therapy of prostate cancer.
    Labrie F
    Prog Brain Res; 2010; 182():321-41. PubMed ID: 20541672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of two non-steroidal antiandrogens on testicular function in prepubertal rats.
    Rulli SB; Gonzalez-Calvar SI; Campo S; Calandra RS
    J Androl; 1995; 16(3):225-32. PubMed ID: 7559155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiandrogen monotherapy: recommendations for the treatment of prostate cancer.
    Sciarra A; Cardi A; Di Silverio F
    Urol Int; 2004; 72(2):91-8. PubMed ID: 14963347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy.
    Kojima S; Suzuki H; Akakura K; Shimbo M; Ichikawa T; Ito H
    J Urol; 2004 Feb; 171(2 Pt 1):679-83. PubMed ID: 14713785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transgenic mouse model for rapid pharmacodynamic evaluation of antiandrogens.
    Ellwood-Yen K; Wongvipat J; Sawyers C
    Cancer Res; 2006 Nov; 66(21):10513-6. PubMed ID: 17079473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormonal and morphologic evaluation of the effects of antiandrogens on the blood supply of the rat prostate.
    Shibata Y; Ono Y; Kashiwagi B; Suzuki K; Fukabori Y; Honma S; Yamanaka H
    Urology; 2003 Nov; 62(5):942-6. PubMed ID: 14624931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-steroidal antiandrogens act as AF-1 agonists under conditions of high androgen-receptor expression.
    Fuse H; Korenaga S; Sakari M; Hiyama T; Ito T; Kimura K; Kato S
    Prostate; 2007 May; 67(6):630-7. PubMed ID: 17342748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.